The top 100 stock
market authors
selected for publication
market authors
selected for publication
Merck & Co. Inc. (MRK) ()
|
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: |
Articles on Merck & Co. Inc. (MRK) by latest | most commented
- Pharmas, Hospitals Fall Due to Health Care Reform Troubles
- Alternate Short Strategy: Put Protection for Less (Part II)
- Why Healthcare Is a Good Defensive Sector
- Why the Dow Is Lagging the S&P 500, Nasdaq
- Options Bearish on Merck
- Pharmaceutical Dollar Rationing by Results
- Smaller Pharma Wins the 'Most Valuable' Race
- Dow Member Year to Date Performance
- Short Sellers Diving into Healthcare
- Pharma M&A: Big Bonds and Small Deals
- Selling Schering Plough, Looking to India, Brazil and South Africa
- IHI: A Closer Look at Medical Device Makers
- Bond Expert: Tuesday Wrap
- 51 Option Ideas for Bears
- Today's Market: Convergence of Reality and Perception
- A Healthy Dose of Funding for Pharma, Biotech
- Biotech Set to Capture 50% of Top 100 Drugs by 2014
- Biotech Set to Dominate Drug Industry Growth
- Playing Health Care Reform with Biotech ETFs IBB and XBI
- The FDA vs. Science on Merck HPV Vaccine
- Merck Needs Schering-Plough
- Proposed Legislation Could Boost Medicare's Ability to Extract Savings on Drugs
- 6 Healthcare Stocks to Watch
- Life Science Looks to Big Pharma for Funding as Caution Still Reigns
- Canadian Fund Portfolio Update
- The New Dow Jones Industrial Average: Calculations and Individual Weightings
- Merck Short Base Rising
- Bio Medical Stock Sector is Where the Action Is
- Amylin Update Post ADA Meeting
- Merck's Heart Failure Drug Candidate Hits the Skids
- 30 Attractive Companies Under $30: Fidelity's Low Priced Stock Fund Part II
- Another Merck Pipeline Setback
- Life Science Companies Get Boost from Capital Markets
- Biggest Health Care Winners Become Biggest Losers After Friday's Market Action
- Health Care Trends Part 2: M&A, Generic Competition, CROs
- FDA Calendar Updates: ABT, AFFY, AZN, LLY, MELA, PFE, SOMX, VPHM
- Thursday Options Recap
- Merck and AstraZeneca: An Uncommon Deal Indeed
- 30 Option Strategies: The New Dow Edition
- Drug Stocks That Are Under the Radar
- Long Term Results of Oncothyreon's Stimuvax Look Promising
-
The Seeking Alpha 100
See all
Seeking Alpha 100 » -
Fastest Climbers
Authors with the largest
increase in followers
in the last 7 days-
1
Philip Davis
-
2
David Fry
-
3
TraderMark
-
4
Bill Gross
-
5
Tyler Durden
Fastest Climbers » -
1
-
Top Commenters
Top commenters,See all
as ranked by their peers
Top Commenters » -
Top Instabloggers
The 100 most activeSee all
Instabloggers.
Top Instabloggers » -
Top StockTalkers
TopSee all
StockTalkers.
Top StockTalkers »
